L. Demir, Duygu Bayır, Ruhengiz Özdoğan, B. Yıldız, M. Dinçer
The Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) have classified RCC according to clinical characteristics into three risk groups: favorable, intermediate, and poor. Previous reports have demonstrated that patients with poor-risk features (according to MSKCC criteria and neutrophil and platelet counts) presented a significantly shorter overall survival (OS) than patients with favorableto intermediate-risk features, and the twoyear survival rate of poor-risk patients did not exceed 7%, while that of the favorableto intermediate-risk patients was 53-75%.4,5
{"title":"A Real-World Comparison of Pazopanib Versus Sunitinib in Metastatic Renal Cell Carcinoma: Focus on Poor-Risk patients, A Single-Center Study","authors":"L. Demir, Duygu Bayır, Ruhengiz Özdoğan, B. Yıldız, M. Dinçer","doi":"10.37047/jos.2020-76764","DOIUrl":"https://doi.org/10.37047/jos.2020-76764","url":null,"abstract":"The Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) have classified RCC according to clinical characteristics into three risk groups: favorable, intermediate, and poor. Previous reports have demonstrated that patients with poor-risk features (according to MSKCC criteria and neutrophil and platelet counts) presented a significantly shorter overall survival (OS) than patients with favorableto intermediate-risk features, and the twoyear survival rate of poor-risk patients did not exceed 7%, while that of the favorableto intermediate-risk patients was 53-75%.4,5","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"153-163"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69818328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Çiçin, Aydın Çiltaş, S. Kılıçkap, B. Öksüzoğlu, D. Uncu, M. Artaç, H. Çınkır, A. Işıkdoğan, F. Dane, M. Aliustaoğlu, H. M. Türk, E. Elkiran, E. Çubukçu, M. Ekenel, F. Ozdemir, A. Gökyer, I. Oztop, A. Alacacıoğlu, Hüseyin Öztürk, B. Aver, M. Ozkan
aTrakya University Faculty of Medicine, Department of Internal Medicine, Division of Oncology, Edirne, TURKEY bGazi University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Ankara, TURKEY cHacettepe University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Ankara, TURKEY dDr. Abdurrahman Yurtarslan Ankara Oncology Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology, Ankara, TURKEY eUniversiy of Health Sciences Ankara Numune Training and Research Hospital, Clinic of Medical Oncology, Ankara, TURKEY fNecmettin Erbakan University Meram Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Konya, TURKEY gGaziantep University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Gaziantep, TURKEY hDicle University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Diyarbakır, TURKEY iMarmara University Pendik Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology, İstanbul, TURKEY jKartal Dr. Lütfi Kirdar Training and Research Hospital, Department of Medical Oncology, İstanbul, TURKEY kBezmialem Vakıf University Faculty of Medicine, Department of Medical Oncology, İstanbul, TURKEY lİnönü University Turgut Ozal Medical Center, Department of Internal Medicine, Division of Medical Oncology, Malatya, TURKEY mAli Osman Sönmez Oncology Hospital, Department of Medical Oncology, Bursa, TURKEY nİstanbul University Istanbul Medical Faculty, Department of Medical Oncology, İstanbul, TURKEY oKaradeniz Technical University Faculty of Medicine, Department of Internal Medicine, Trabzon, TURKEY pDokuz Eylül University Faculty of Medicine, Department of Medical Oncology, İzmir, TURKEY rIzmir Katip Çelebi University Atatürk Training and Research Hospital, Department of Medical Oncology, İzmir, TURKEY sPfizer Pharmaceuticals, Medical Oncology Department, İstanbul, TURKEY tErciyes University Faculty of Medicine, Department of Internal Medicine, Kayseri, TURKEY
{"title":"Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study","authors":"I. Çiçin, Aydın Çiltaş, S. Kılıçkap, B. Öksüzoğlu, D. Uncu, M. Artaç, H. Çınkır, A. Işıkdoğan, F. Dane, M. Aliustaoğlu, H. M. Türk, E. Elkiran, E. Çubukçu, M. Ekenel, F. Ozdemir, A. Gökyer, I. Oztop, A. Alacacıoğlu, Hüseyin Öztürk, B. Aver, M. Ozkan","doi":"10.37047/jos.2020-75080","DOIUrl":"https://doi.org/10.37047/jos.2020-75080","url":null,"abstract":"aTrakya University Faculty of Medicine, Department of Internal Medicine, Division of Oncology, Edirne, TURKEY bGazi University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Ankara, TURKEY cHacettepe University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Ankara, TURKEY dDr. Abdurrahman Yurtarslan Ankara Oncology Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology, Ankara, TURKEY eUniversiy of Health Sciences Ankara Numune Training and Research Hospital, Clinic of Medical Oncology, Ankara, TURKEY fNecmettin Erbakan University Meram Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Konya, TURKEY gGaziantep University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Gaziantep, TURKEY hDicle University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Diyarbakır, TURKEY iMarmara University Pendik Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology, İstanbul, TURKEY jKartal Dr. Lütfi Kirdar Training and Research Hospital, Department of Medical Oncology, İstanbul, TURKEY kBezmialem Vakıf University Faculty of Medicine, Department of Medical Oncology, İstanbul, TURKEY lİnönü University Turgut Ozal Medical Center, Department of Internal Medicine, Division of Medical Oncology, Malatya, TURKEY mAli Osman Sönmez Oncology Hospital, Department of Medical Oncology, Bursa, TURKEY nİstanbul University Istanbul Medical Faculty, Department of Medical Oncology, İstanbul, TURKEY oKaradeniz Technical University Faculty of Medicine, Department of Internal Medicine, Trabzon, TURKEY pDokuz Eylül University Faculty of Medicine, Department of Medical Oncology, İzmir, TURKEY rIzmir Katip Çelebi University Atatürk Training and Research Hospital, Department of Medical Oncology, İzmir, TURKEY sPfizer Pharmaceuticals, Medical Oncology Department, İstanbul, TURKEY tErciyes University Faculty of Medicine, Department of Internal Medicine, Kayseri, TURKEY","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"87-95"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pituitary Gland Metastasis of Breast Cancer: A Rare Case Report and Review of the Literature","authors":"M. Şimşek","doi":"10.37047/jos.2020-75309","DOIUrl":"https://doi.org/10.37047/jos.2020-75309","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"127-130"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Docetaxel, Cisplatin, and Fluorouracil Combination Chemotherapy in Neoadjuvant Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study","authors":"Öztürk Ateş, E. Yekedüz, S. Kılıçkap, Ş. Yalçın","doi":"10.37047/jos.2020-76836","DOIUrl":"https://doi.org/10.37047/jos.2020-76836","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"28 6 1","pages":"173-178"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69818788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Beypınar, H. Demir, M. Araz, D. Beypinar, M. Uysal
10 The infusional chemotherapy regimen, especially in gastrointestinal cancers, has a long-term need for central venous catheterization. Implantable ports (IP) are increasingly used for the administration of chemotherapy and supportive treatment to cancer patients. The IPs may be complicated with thrombosis in both upper and lower extremities, during placement or long-term follow-up which is associated with treatment delay, increasing financial burden, morbidity and mortality.1-6 IP thrombosis is mostly seen in the first three months and rarely seen beyond this period. The most preferred location for IPs is the subclavian vein, which is implanted by the Seldinger technique via a cephalic vein.7 In appropriate patients, femoral IPs can also be used.8 The main cause of thrombosis is considered to be direct vascular damage.4,9,10 There are mainly three mechanisms of IP thrombosis. The first mechanism is an acute reaction of clotting, which is induced with a fibrin sheath and is related to the subsequent risk of thrombosis. The second mechanism is the lumen thrombosis of the catheter, which may be thawed with thrombolytic agents. Blood vessel thrombosis is the most severe The Comparison of Central Venous Port Catheters in Gastrointestinal Cancer Treatment
{"title":"The Comparison of Central Venous Port Catheters in Gastrointestinal Cancer Treatment","authors":"I. Beypınar, H. Demir, M. Araz, D. Beypinar, M. Uysal","doi":"10.37047/jos.2019-73122","DOIUrl":"https://doi.org/10.37047/jos.2019-73122","url":null,"abstract":"10 The infusional chemotherapy regimen, especially in gastrointestinal cancers, has a long-term need for central venous catheterization. Implantable ports (IP) are increasingly used for the administration of chemotherapy and supportive treatment to cancer patients. The IPs may be complicated with thrombosis in both upper and lower extremities, during placement or long-term follow-up which is associated with treatment delay, increasing financial burden, morbidity and mortality.1-6 IP thrombosis is mostly seen in the first three months and rarely seen beyond this period. The most preferred location for IPs is the subclavian vein, which is implanted by the Seldinger technique via a cephalic vein.7 In appropriate patients, femoral IPs can also be used.8 The main cause of thrombosis is considered to be direct vascular damage.4,9,10 There are mainly three mechanisms of IP thrombosis. The first mechanism is an acute reaction of clotting, which is induced with a fibrin sheath and is related to the subsequent risk of thrombosis. The second mechanism is the lumen thrombosis of the catheter, which may be thawed with thrombolytic agents. Blood vessel thrombosis is the most severe The Comparison of Central Venous Port Catheters in Gastrointestinal Cancer Treatment","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"10-14"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Karakaş, O. Dizdar, K. Kösemehmetoğlu, U. B. Bozbulut, Metin Demir, G. Gedıkoğlu, F. Söylemezoğlu, A. Turker, A. Kars
Malignant peripheral nerve sheath tumor (MPNST) is an uncommon soft tissue sarcoma that originates from the peripheral nerves and is hypothesized to be of neural crest origin.1 The incidence of MPNST is 1:100.000/year and accounts for 5-10% of all soft tissue sarcomas.2 Approximately 50% of MPNSTs occur sporadically, the remaining arises secondary to prior radiation exposure and in patients with neurofibromatosis type 1 (NF1).3-5 In the NF1 patients, MPNST usually originates from plexiform neurofibromas and atypical neurofibromas. The lifetime risk of developing MPNST in these patients is around 8-13%.5-8 MPNSTs often arise from large and medium-sized nerves, located in the extremities in 33J Oncol Sci. 2020;6(1):23-8
{"title":"Multimodality Treatment in Malignant Peripheral Nerve Sheath Tumors","authors":"Y. Karakaş, O. Dizdar, K. Kösemehmetoğlu, U. B. Bozbulut, Metin Demir, G. Gedıkoğlu, F. Söylemezoğlu, A. Turker, A. Kars","doi":"10.37047/jos.2019-73127","DOIUrl":"https://doi.org/10.37047/jos.2019-73127","url":null,"abstract":"Malignant peripheral nerve sheath tumor (MPNST) is an uncommon soft tissue sarcoma that originates from the peripheral nerves and is hypothesized to be of neural crest origin.1 The incidence of MPNST is 1:100.000/year and accounts for 5-10% of all soft tissue sarcomas.2 Approximately 50% of MPNSTs occur sporadically, the remaining arises secondary to prior radiation exposure and in patients with neurofibromatosis type 1 (NF1).3-5 In the NF1 patients, MPNST usually originates from plexiform neurofibromas and atypical neurofibromas. The lifetime risk of developing MPNST in these patients is around 8-13%.5-8 MPNSTs often arise from large and medium-sized nerves, located in the extremities in 33J Oncol Sci. 2020;6(1):23-8","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"23-28"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Gürbüz, P. K. Tolunay, E. Akkuş, Ümit Eroğlu, A. Heper, F. Senler
Sarcomas are malignant neoplasms that arise from mesenchymal tissues. Sarcomas are a rare type of solid cancers, encompassing more than one hundred subtypes, and occur at any age.1 Sarcomas of the meninges may originate primarily from mesenchymal cells or may be metastases of extracranial soft tissue sarcomas.2 Symptoms such as nausea, vomiting, headache, seizure, and spinal cord compression may occur depending on the size and location of the tumor. Cranial magnetic resonance imaging (MRI) is often used for diagnosis. The primary treatment for sarcomas is surgery; other treatment options include radiotherapy (RT), chemotherapy (CT), targeted therapies, and immunotherapy.3 Though RT is one of the risk factors for sarcoma development, RT-related dural sarcomas are extremely rare.2 There is no consensus on the management of these extremely rare, malignant neoplasms. Here, the authors report a case of RT-related dural sarcoma and its management.
{"title":"Radiotherapy-Related Dural Sarcoma and Its Management: Case Report","authors":"M. Gürbüz, P. K. Tolunay, E. Akkuş, Ümit Eroğlu, A. Heper, F. Senler","doi":"10.37047/jos.2020-76458","DOIUrl":"https://doi.org/10.37047/jos.2020-76458","url":null,"abstract":"Sarcomas are malignant neoplasms that arise from mesenchymal tissues. Sarcomas are a rare type of solid cancers, encompassing more than one hundred subtypes, and occur at any age.1 Sarcomas of the meninges may originate primarily from mesenchymal cells or may be metastases of extracranial soft tissue sarcomas.2 Symptoms such as nausea, vomiting, headache, seizure, and spinal cord compression may occur depending on the size and location of the tumor. Cranial magnetic resonance imaging (MRI) is often used for diagnosis. The primary treatment for sarcomas is surgery; other treatment options include radiotherapy (RT), chemotherapy (CT), targeted therapies, and immunotherapy.3 Though RT is one of the risk factors for sarcoma development, RT-related dural sarcomas are extremely rare.2 There is no consensus on the management of these extremely rare, malignant neoplasms. Here, the authors report a case of RT-related dural sarcoma and its management.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"179-182"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69818312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
atinocytes located in the basal epidermis, which firstly infiltrate the epidermis and then the dermis. Clinically, it usually occurs on the face and neck.1,2 BCC has five main clinical variants: nodular-ulcerative, superficial, sclerosing-morphea, pigment-ulcerated and fibroepithelial.3 The incidence rate of BCCs in the US reportedly spiked by 145% between 2000 and 2010 with the reasons for this significant increase including the aging of the patient population, increased awareness of the overall population, increased number of surgical cases, better record-keeping, and UV radiation.4
{"title":"Vismodegib for Patients with Advanced Basal Cell Carcinoma: One Center’s Experience","authors":"H. Çınkır, O. Sever, F. Teker","doi":"10.37047/jos.2019-71992","DOIUrl":"https://doi.org/10.37047/jos.2019-71992","url":null,"abstract":"atinocytes located in the basal epidermis, which firstly infiltrate the epidermis and then the dermis. Clinically, it usually occurs on the face and neck.1,2 BCC has five main clinical variants: nodular-ulcerative, superficial, sclerosing-morphea, pigment-ulcerated and fibroepithelial.3 The incidence rate of BCCs in the US reportedly spiked by 145% between 2000 and 2010 with the reasons for this significant increase including the aging of the patient population, increased awareness of the overall population, increased number of surgical cases, better record-keeping, and UV radiation.4","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"5-9"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Yalçın, A. Sezer, A. Sümbül, Samet Rahatli, Ö. Altundağ, A. M. Sedef, O. Ozyılkan
Many biomarkers have emerged as prognostic and predictive markers for NSCLC. Among them, the common biomarkers are the epidermal growth factor receptor (EGFR), 5 endonuclease enzyme of nucleotide excision repair (ERCC1), Kirsten sarcoma virus, which is a proto-oncogene (K-ras), and regulator subunit of ribonucleotide reductase. Besides, there is huge evidence suggesting that there might be a prognosis between NSCLC and BRCA1, XOR.1-3
{"title":"Relationship Between Xanthine Oxidoreductase Activity and BRCA1 Levels in Patients with Stage IIIA and IIIB Non-Small Cell Lung Cancer Being Treated with Neoadjuvant Chemotherapy","authors":"S. Yalçın, A. Sezer, A. Sümbül, Samet Rahatli, Ö. Altundağ, A. M. Sedef, O. Ozyılkan","doi":"10.37047/jos.2019-71890","DOIUrl":"https://doi.org/10.37047/jos.2019-71890","url":null,"abstract":"Many biomarkers have emerged as prognostic and predictive markers for NSCLC. Among them, the common biomarkers are the epidermal growth factor receptor (EGFR), 5 endonuclease enzyme of nucleotide excision repair (ERCC1), Kirsten sarcoma virus, which is a proto-oncogene (K-ras), and regulator subunit of ribonucleotide reductase. Besides, there is huge evidence suggesting that there might be a prognosis between NSCLC and BRCA1, XOR.1-3","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Kumbasar, B. Duman, M. Yuksel, S. Bozdağ, Pelin Kilic, Acelya Yilmazer Aktuna, C. Gurcan, Tuğba Şen, Ç. Aydemir, D. Öztop, A. Uslu, G. Gurman
familiar, they indicate an advanced healthcare approach. In the 20th century, bone marrow transplantation exhibited a high expectation in the medical community and had immense popularity in society ever since. In clinical practice, the designation of “bone marrow transplantation” has been replaced with “stem cell transplantation, when stem cell sources other than bone marrow were discovered. Within the past 30 years, Ankara University Stem Cell Transplantation Unit executed around 3000 stem cell transplants.
{"title":"Stem Cells and Psyche: Perspectives and a Review of the Literature","authors":"H. Kumbasar, B. Duman, M. Yuksel, S. Bozdağ, Pelin Kilic, Acelya Yilmazer Aktuna, C. Gurcan, Tuğba Şen, Ç. Aydemir, D. Öztop, A. Uslu, G. Gurman","doi":"10.37047/jos.2019-71899","DOIUrl":"https://doi.org/10.37047/jos.2019-71899","url":null,"abstract":"familiar, they indicate an advanced healthcare approach. In the 20th century, bone marrow transplantation exhibited a high expectation in the medical community and had immense popularity in society ever since. In clinical practice, the designation of “bone marrow transplantation” has been replaced with “stem cell transplantation, when stem cell sources other than bone marrow were discovered. Within the past 30 years, Ankara University Stem Cell Transplantation Unit executed around 3000 stem cell transplants.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"6 1","pages":"103-118"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69817528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：